The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...
The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.
Thousands of men suffering from prostate cancer are set to gain access to a life-extending drug on the NHS following a significant expansion of eligibility criteria. Previously, the hormone therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results